The CMHC Education Resource Center offers a single access point for educational resources and online courses featuring the expert content and faculty from CMHC live events. Stay current on the latest clinical research and strategies, while testing your knowledge of essential topics in cardiometabolic risk management and CVD prevention. Select from a comprehensive array of complimentary CME-CE activities in a variety of formats to meet your needs, available on-demand and on-the-go!

*New* Featured Activity

Infographic: Breaking Through Inertia: How to Initiate and Maintain Insulin Therapy in Patients with Type 2 Diabetes

Earn 1.5 AMA/AAFP Prescribed Credits



This interactive infographic covers a variety of topics surrounding the role of insulin therapy in type 2 diabetes (T2D) management, including practical pearls for initiation and maintenance of insulin therapy, how insulin therapy fits in with other T2D treatment options, and emerging insulin options.

The information is presented in an interactive format, which contains a mix of high-impact visuals, infographics, expert faculty videos, as well as resources and suggested readings, all organized into different segments to facilitate learning.



Access Now

*NEW* Featured Activity

Journal Review: The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

Earn 0.75 AMA/ANCC/ACPE Credits


Metabolic dysfunction-associated steatotic liver disease (MASLD) affects an estimated 25-30% of people in the United States and can often progress to Metabolic dysfunction-associated steatohepatitis (MASH) and cirrhosis. MASH represents a metabolic-driven array of multi-organ pathology that intersects with obesity, prediabetes, type 2 diabetes, and cardiovascular ailments. Many agents are currently in development for treatment of MASH, including glucagon-like peptide-1 receptor agonists (GLP1-Ras). Although not FDA-approved specifically for MASLD, GLP1-RAs is utilized for obesity and type 2 diabetes treatment. It has demonstrated the ability to reverse steatohepatitis, lower cardiovascular risk, and is considered safe for use across various stages of MASLD, regardless of fibrosis presence. This review outlines the role of GLP1-RAs in treating MASLD/MASH.

Access Now